Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Legend Biotech Corporation - American Depositary Shares
(NQ:
LEGN
)
17.50
-0.22 (-1.24%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Legend Biotech Corporation - American Depositary Shares
< Previous
1
2
3
4
5
Next >
Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use
January 21, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 17, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
December 06, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
November 13, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights
November 12, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
November 03, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results
October 29, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
August 26, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Appoints Carlos Santos as Chief Financial Officer
August 18, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights
August 11, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Host Investor Conference Call on Second Quarter 2025 Results
July 28, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting
June 03, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT
May 22, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
May 19, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Reports First Quarter 2025 Results and Recent Highlights
May 13, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results
April 29, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights
March 11, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results
February 25, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 19, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights
November 12, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
November 07, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma
December 09, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
November 05, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Appoints Alan Bash as President of CARVYKTI®
November 04, 2024
Newly created position to lead efforts focused on continued growth and sales
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results
October 24, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
October 03, 2024
New 31,000 square-foot facility will enhance Legend’s leading cell therapy portfolio and expand Legend’s R&D capabilities as a global cell therapy leader
From
Legend Biotech USA Inc.
Via
GlobeNewswire
CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line
September 27, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 20, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights
August 09, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
